In the treatment of pancreatic cancer, fisetin can induce the expression of RFXAP (regulatory factor X-associated protein), which leads to the upregulation of the KDM4A expression and the downregulation of H3K36 methylation, thus inhibiting the DNA damage repair pathway [29]. This evidence concerns the gene KDM4A and familial pancreatic carcinoma.